Distinct cAMP Signaling Microdomains Differentially Regulate Melanosomal pH and Pigmentation.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
10 2023
Historique:
received: 20 12 2022
revised: 24 03 2023
accepted: 12 04 2023
pmc-release: 01 10 2024
medline: 25 9 2023
pubmed: 5 5 2023
entrez: 4 5 2023
Statut: ppublish

Résumé

cAMP signaling is a well-established regulator of melanin synthesis. Two distinct cAMP signaling pathways-the transmembrane adenylyl cyclase pathway, activated primarily by the MC1R, and the soluble adenylyl cyclase (sAC) pathway-affect melanin synthesis. The sAC pathway affects melanin synthesis by regulating melanosomal pH, and the MC1R pathway affects melanin synthesis by regulating gene expression and post-translational modifications. However, whether MC1R genotype affects melanosomal pH is poorly understood. We now report that loss of function MC1R does not affect melanosomal pH. Thus, sAC signaling appears to be the only cAMP signaling pathway that regulates melanosomal pH. We also addressed whether MC1R genotype affects sAC-dependent regulation of melanin synthesis. Although sAC loss of function in wild-type human melanocytes stimulates melanin synthesis, sAC loss of function has no effect on melanin synthesis in MC1R nonfunctional human and mouse melanocytes or skin and hair melanin in e/e mice. Interestingly, activation of transmembrane adenylyl cyclases, which increases epidermal eumelanin synthesis in e/e mice, leads to enhanced production of eumelanin in sAC-knockout mice relative to that in sAC wild-type mice. Thus, MC1R- and sAC-dependent cAMP signaling pathways define distinct mechanisms that regulate melanosomal pH and pigmentation.

Identifiants

pubmed: 37142186
pii: S0022-202X(23)02044-4
doi: 10.1016/j.jid.2023.04.011
pmc: PMC10524761
mid: NIHMS1898900
pii:
doi:

Substances chimiques

Melanins 0
Adenylyl Cyclases EC 4.6.1.1
Receptor, Melanocortin, Type 1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2019-2029.e3

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR076029
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR077664
Pays : United States
Organisme : NIEHS NIH HHS
ID : R21 ES032347
Pays : United States
Organisme : BLRD VA
ID : I01 BX003668
Pays : United States

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Exp Cell Res. 2001 Jan 15;262(2):197-208
pubmed: 11139343
Elife. 2014 Dec 16;3:e04543
pubmed: 25513726
J Exp Clin Cancer Res. 2017 Oct 11;36(1):142
pubmed: 29020973
Int J Mol Sci. 2018 Sep 08;19(9):
pubmed: 30205563
Mol Biol Cell. 2020 Nov 15;31(24):2687-2702
pubmed: 32966160
Pigment Cell Melanoma Res. 2009 Oct;22(5):623-34
pubmed: 19493315
Cell. 2007 Mar 9;128(5):853-64
pubmed: 17350573
J Biol Chem. 2006 Jun 23;281(25):17253-17258
pubmed: 16627466
J Biol Chem. 1987 Mar 25;262(9):4024-33
pubmed: 3031058
Nature. 2006 Sep 21;443(7109):340-4
pubmed: 16988713
Pigment Cell Melanoma Res. 2009 Oct;22(5):635-44
pubmed: 19558415
Int J Ophthalmol. 2014 Oct 18;7(5):872-8
pubmed: 25349810
Pigment Cell Melanoma Res. 2016 Nov;29(6):607-618
pubmed: 27454804
Hum Mol Genet. 2005 Aug 1;14(15):2145-54
pubmed: 15972726
Nat Neurosci. 2006 Oct;9(10):1257-64
pubmed: 16964251
J Invest Dermatol. 2017 Sep;137(9):1887-1894
pubmed: 28502801
Am J Hum Genet. 2001 Oct;69(4):765-73
pubmed: 11500805
J Invest Dermatol. 2001 Jul;117(1):158-9
pubmed: 11442766
Int J Mol Sci. 2013 Jun 07;14(6):12222-48
pubmed: 23749111
Science. 2000 Jul 28;289(5479):625-8
pubmed: 10915626
J Invest Dermatol. 2001 Jul;117(1):3-15
pubmed: 11442744
Pigment Cell Res. 2002 Jun;15(3):225-32
pubmed: 12028587
J Invest Dermatol. 2001 Aug;117(2):294-300
pubmed: 11511307
Front Genet. 2016 May 31;7:95
pubmed: 27303435
Sci Signal. 2018 Nov 06;11(555):
pubmed: 30401788
J Biol Chem. 2013 Nov 15;288(46):33283-91
pubmed: 24100033
J Invest Dermatol. 2021 Jul;141(7):1819-1829
pubmed: 33609553
Pigment Cell Melanoma Res. 2017 May;30(3):372-377
pubmed: 28271633
Gene. 2001 Oct 17;277(1-2):49-62
pubmed: 11602344
Pigment Cell Melanoma Res. 2014 Sep;27(5):721-33
pubmed: 24814217
Annu Rev Genomics Hum Genet. 2019 Aug 31;20:41-72
pubmed: 31100995
Mutat Res. 2010 Oct;705(2):141-153
pubmed: 20601102
Pigment Cell Melanoma Res. 2021 Jul;34(4):730-747
pubmed: 33751833
Exp Dermatol. 2011 Aug;20(8):681-4
pubmed: 21615505
J Natl Cancer Inst. 2002 Mar 20;94(6):446-54
pubmed: 11904317
Pigment Cell Melanoma Res. 2011 Aug;24(4):605-13
pubmed: 21535429
Biochim Biophys Acta Mol Basis Dis. 2017 Oct;1863(10 Pt A):2448-2461
pubmed: 28259754
Pigment Cell Res. 2006 Apr;19(2):154-62
pubmed: 16524431
Bioessays. 2013 Aug;35(8):672-6
pubmed: 23650156
Pigment Cell Res. 1993 Oct;6(5):348-53
pubmed: 8302773
J Invest Dermatol. 2021 Jul;141(7):1810-1818.e6
pubmed: 33549605
Int J Cancer. 2006 Oct 15;119(8):1976-84
pubmed: 16721784
Exp Dermatol. 2008 May;17(5):395-404
pubmed: 18177348
Photochem Photobiol. 2008 May-Jun;84(3):539-49
pubmed: 18435612
J Invest Dermatol. 2012 Sep;132(9):2255-62
pubmed: 22572817
Pigment Cell Melanoma Res. 2014 Mar;27(2):244-52
pubmed: 24387634
FASEB J. 2010 Oct;24(10):3850-60
pubmed: 20519635
Nat Genet. 1995 Nov;11(3):328-30
pubmed: 7581459
Pigment Cell Melanoma Res. 2014 Sep;27(5):699-720
pubmed: 24807163
J Biol Chem. 2009 Jul 10;284(28):18699-706
pubmed: 19389708
J Invest Dermatol. 1997 Jun;108(6):838-42
pubmed: 9182807
Trends Endocrinol Metab. 2001 Oct;12(8):366-70
pubmed: 11551811
Exp Cell Res. 2001 Aug 1;268(1):26-35
pubmed: 11461115
Front Oncol. 2022 Nov 22;12:887770
pubmed: 36483028
Curr Opin Cell Biol. 2014 Aug;29:1-7
pubmed: 24662021
Int J Mol Sci. 2020 Jul 20;21(14):
pubmed: 32698502
J Cell Physiol. 2009 Sep;220(3):640-54
pubmed: 19452503
Cell Rep. 2022 Sep 27;40(13):111412
pubmed: 36170819
Oncotarget. 2016 Jul 19;7(29):45597-45607
pubmed: 27323809

Auteurs

Maftuna Yusupova (M)

Department of Dermatology, NewYork-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.

Dalee Zhou (D)

Department of Dermatology, NewYork-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.

Jaewon You (J)

Department of Dermatology, NewYork-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.

Jeydi Gonzalez-Guzman (J)

Department of Biology, College of Arts and Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Megha B Ghanta (MB)

Department of Biology, College of Arts and Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Hong Pu (H)

Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

Zalfa Abdel-Malek (Z)

Department of Dermatology, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.

Qiuying Chen (Q)

Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA.

Steven S Gross (SS)

Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA.

John D'Orazio (J)

Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

Shosuke Ito (S)

Institute for Melanin Chemistry, Fujita Health University, Toyoake, Japan.

Kazumasa Wakamatsu (K)

Institute for Melanin Chemistry, Fujita Health University, Toyoake, Japan.

Melissa L Harris (ML)

Department of Biology, College of Arts and Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Jonathan H Zippin (JH)

Department of Dermatology, NewYork-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA; Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA; Englander Institute of Precision Medicine, Weill Cornell Medical College, New York, New York, USA. Electronic address: jhzippin@med.cornell.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH